These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24022820)

  • 1. Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation.
    Eymin G; Jaffer AK
    J Thromb Thrombolysis; 2014; 37(2):87-96. PubMed ID: 24022820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation.
    Eymin G; Jaffer AK
    J Thromb Thrombolysis; 2014; 37(2):87-96. PubMed ID: 25298982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
    Adam SS; McDuffie JR; Ortel TL; Williams JW
    Ann Intern Med; 2012 Dec; 157(11):796-807. PubMed ID: 22928173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants in patients with cancer.
    Bossaer JB; Covert KL
    Am J Health Syst Pharm; 2019 Jul; 76(14):1019-1027. PubMed ID: 31361880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 9. New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds.
    Dimitropoulos G; Rahim SMZ; Moss AS; Lip GYH
    Expert Opin Investig Drugs; 2018 Jan; 27(1):71-86. PubMed ID: 29224364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving prevention and treatment of venous thromboembolism: clinical trial results.
    Mahan C; Spyropoulos AC
    J Med Econ; 2012; 15(4):611-22. PubMed ID: 22372589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism.
    Chan NC; Eikelboom JW
    Blood; 2019 May; 133(21):2269-2278. PubMed ID: 30926593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Towards new indications for direct oral anticoagulants].
    Fontana P; Robert-Ebadi H; Righini M
    Rev Med Suisse; 2021 Jan; 17(720-1):20-23. PubMed ID: 33443825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
    Yong CM; Boyle AJ
    Curr Vasc Pharmacol; 2010 Jan; 8(1):5-11. PubMed ID: 19485937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary Venous Thromboembolism in an Acutely Ill Medical Patient Receiving Rivaroxaban.
    Saleem A
    J Coll Physicians Surg Pak; 2017 Sep; 27(9):S129-S130. PubMed ID: 28969751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature.
    Dentali F; Sironi AP; Gianni M; Orlandini F; Guasti L; Grandi AM; Franchini M; Ageno W; Squizzato A
    Semin Thromb Hemost; 2015 Oct; 41(7):774-87. PubMed ID: 26408921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
    Proietti M; Lip GY
    Vasc Health Risk Manag; 2016; 12():45-51. PubMed ID: 27013883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.